Staar Surgical: Sidoti Downgrades Neutral, Raises PT to $28
ByAinvest
Tuesday, Aug 5, 2025 11:37 am ET1min read
ALC--
Staar Surgical Co. (STAA) experienced a significant change in its market outlook following a recent downgrade from Sidoti Research. The firm has revised its price target for STAA to $28, indicating a potential upside of 124.01% from the current price of $18.49 [3]. This move comes amidst a series of positive and negative signals surrounding the stock.
On Monday, August 4, 2025, STAA's stock price gained 4.11%, rising from $17.76 to $18.49. The stock has shown a mixed trend in the short term, with a 4.11% gain over the past two weeks. The trading volume increased significantly, with 535,000 more shares traded compared to the previous day, totaling 1 million shares traded for approximately $22.50 million [1].
Technical analysts have provided a mixed forecast for STAA. While the stock holds several buy signals from both short and long-term moving averages, there are also indications of potential short-term falls. The stock is expected to fall by -5.14% over the next three months, with a 90% probability of holding a price between $15.02 and $18.17 at the end of this period [1].
The stock has shown resilience, finding support at $17.76 and $18.47. However, a breakdown below these levels could issue sell signals. Additionally, the stock had a Golden Star Signal on July 17, 2025, which is a rare combination of short-term and long-term moving averages meeting the price line, often followed by long and strong gains [1].
Staar Surgical Co. is set to release its Q2 2025 earnings on August 6, 2025. The consensus estimate for Q2 2025 revenue is $40.67 million, with earnings expected to be -$0.66 per share. The full year 2025 revenue is expected to be $255.27 million, with earnings estimated at -$1.73 per share [2].
The company has also entered into a definitive agreement and plan of merger with Alcon Research, LLC. Alcon will acquire STAA for $28.00 per share in an all-cash transaction, with the deal expected to close by August 4, 2026. STAA's stock will be delisted from NASDAQ post-close, and the company will continue to exist as a wholly owned subsidiary [3].
Despite the mixed signals and the upcoming merger, Sidoti Research has raised its price target for STAA to $28, indicating a potential upside. Investors should closely monitor the earnings report and the progress of the merger for further insights into STAA's future performance.
References
[1] https://stockinvest.us/stock/STAA
[2] https://finance.yahoo.com/news/staar-surgical-co-staa-q2-140137202.html
[3] https://www.stocktitan.net/sec-filings/STAA/8-k-staar-surgical-co-reports-material-event-810347cabb0b.html
STAA--
Staar Surgical: Sidoti Downgrades Neutral, Raises PT to $28
Title: Staar Surgical: Sidoti Downgrades Neutral, Raises PT to $28Staar Surgical Co. (STAA) experienced a significant change in its market outlook following a recent downgrade from Sidoti Research. The firm has revised its price target for STAA to $28, indicating a potential upside of 124.01% from the current price of $18.49 [3]. This move comes amidst a series of positive and negative signals surrounding the stock.
On Monday, August 4, 2025, STAA's stock price gained 4.11%, rising from $17.76 to $18.49. The stock has shown a mixed trend in the short term, with a 4.11% gain over the past two weeks. The trading volume increased significantly, with 535,000 more shares traded compared to the previous day, totaling 1 million shares traded for approximately $22.50 million [1].
Technical analysts have provided a mixed forecast for STAA. While the stock holds several buy signals from both short and long-term moving averages, there are also indications of potential short-term falls. The stock is expected to fall by -5.14% over the next three months, with a 90% probability of holding a price between $15.02 and $18.17 at the end of this period [1].
The stock has shown resilience, finding support at $17.76 and $18.47. However, a breakdown below these levels could issue sell signals. Additionally, the stock had a Golden Star Signal on July 17, 2025, which is a rare combination of short-term and long-term moving averages meeting the price line, often followed by long and strong gains [1].
Staar Surgical Co. is set to release its Q2 2025 earnings on August 6, 2025. The consensus estimate for Q2 2025 revenue is $40.67 million, with earnings expected to be -$0.66 per share. The full year 2025 revenue is expected to be $255.27 million, with earnings estimated at -$1.73 per share [2].
The company has also entered into a definitive agreement and plan of merger with Alcon Research, LLC. Alcon will acquire STAA for $28.00 per share in an all-cash transaction, with the deal expected to close by August 4, 2026. STAA's stock will be delisted from NASDAQ post-close, and the company will continue to exist as a wholly owned subsidiary [3].
Despite the mixed signals and the upcoming merger, Sidoti Research has raised its price target for STAA to $28, indicating a potential upside. Investors should closely monitor the earnings report and the progress of the merger for further insights into STAA's future performance.
References
[1] https://stockinvest.us/stock/STAA
[2] https://finance.yahoo.com/news/staar-surgical-co-staa-q2-140137202.html
[3] https://www.stocktitan.net/sec-filings/STAA/8-k-staar-surgical-co-reports-material-event-810347cabb0b.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet